These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 32418227)

  • 41. The Leishmania donovani Ortholog of the Glycosylphosphatidylinositol Anchor Biosynthesis Cofactor PBN1 Is Essential for Host Infection.
    Roberts A; Nagar R; Brandt C; Harcourt K; Clare S; Ferguson MAJ; Wright GJ
    mBio; 2022 Jun; 13(3):e0043322. PubMed ID: 35420475
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.
    Mizbani A; Taheri T; Zahedifard F; Taslimi Y; Azizi H; Azadmanesh K; Papadopoulou B; Rafati S
    Vaccine; 2009 Dec; 28(1):53-62. PubMed ID: 19818721
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani.
    Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S
    Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Generation and evaluation of A2-expressing Lactococcus lactis live vaccines against Leishmania donovani in BALB/c mice.
    Yam KK; Hugentobler F; Pouliot P; Stern AM; Lalande JD; Matlashewski G; Olivier M; Cousineau B
    J Med Microbiol; 2011 Sep; 60(Pt 9):1248-1260. PubMed ID: 21527547
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibody responses induced by Leish-Tec®, an A2-based vaccine for visceral leishmaniasis, in a heterogeneous canine population.
    Testasicca MC; dos Santos MS; Machado LM; Serufo AV; Doro D; Avelar D; Tibúrcio AM; Abrantes Cde F; Machado-Coelho GL; Grimaldi G; Gazzinelli RT; Fernandes AP
    Vet Parasitol; 2014 Aug; 204(3-4):169-76. PubMed ID: 24863572
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A Non-pathogenic Recombinant Leishmania Expressing Lipophosphoglycan 3 Against Experimental Infection with Leishmania infantum.
    Pirdel L; Farajnia S
    Scand J Immunol; 2017 Jul; 86(1):15-22. PubMed ID: 28426153
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
    Campbell SA; Alawa J; Doro B; Henriquez FL; Roberts CW; Nok A; Alawa CB; Alsaadi M; Mullen AB; Carter KC
    Vaccine; 2012 Feb; 30(7):1357-63. PubMed ID: 22210224
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery of novel vaccine candidates and drug targets against visceral leishmaniasis using proteomics and transcriptomics.
    Kumari S; Kumar A; Samant M; Singh N; Dube A
    Curr Drug Targets; 2008 Nov; 9(11):938-47. PubMed ID: 18991606
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel recombinant Leishmania donovani p45, a partial coding region of methionine aminopeptidase, generates protective immunity by inducing a Th1 stimulatory response against experimental visceral leishmaniasis.
    Gupta R; Kushawaha PK; Tripathi CD; Sundar S; Dube A
    Int J Parasitol; 2012 May; 42(5):429-35. PubMed ID: 22502587
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapy with radio-attenuated vaccine in experimental murine visceral leishmaniasis showed enhanced T cell and inducible nitric oxide synthase levels, suppressed tumor growth factor-beta production with higher expression of some signaling molecules.
    Datta S; Roy S; Manna M
    Braz J Infect Dis; 2015; 19(1):36-42. PubMed ID: 25532783
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Leishmania genome analysis and high-throughput immunological screening identifies tuzin as a novel vaccine candidate against visceral leishmaniasis.
    Lakshmi BS; Wang R; Madhubala R
    Vaccine; 2014 Jun; 32(30):3816-22. PubMed ID: 24814525
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New Vaccine Formulations Containing a Modified Version of the Amastigote 2 Antigen and the Non-Virulent
    Almeida APMM; Machado LFM; Doro D; Nascimento FC; Damasceno L; Gazzinelli RT; Fernandes AP; Junqueira C
    Front Immunol; 2018; 9():465. PubMed ID: 29599776
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1 kDa offers long-lasting protection against experimental visceral leishmaniasis.
    Kumari S; Samant M; Misra P; Khare P; Sisodia B; Shasany AK; Dube A
    Vaccine; 2008 Oct; 26(45):5700-11. PubMed ID: 18762224
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genetically Modified Live Attenuated Leishmania donovani Parasites Induce Innate Immunity through Classical Activation of Macrophages That Direct the Th1 Response in Mice.
    Bhattacharya P; Dey R; Dagur PK; Kruhlak M; Ismail N; Debrabant A; Joshi AB; Akue A; Kukuruga M; Takeda K; Selvapandiyan A; McCoy JP; Nakhasi HL
    Infect Immun; 2015 Oct; 83(10):3800-15. PubMed ID: 26169275
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular, biochemical characterization and assessment of immunogenic potential of cofactor-independent phosphoglycerate mutase against Leishmania donovani: a step towards exploring novel vaccine candidate.
    Tandon R; Chandra S; Baharia RK; Misra P; Das S; Rawat K; Siddiqi MI; Sundar S; Dube A
    Parasitology; 2018 Apr; 145(4):508-526. PubMed ID: 28691653
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Single dose novel Salmonella vaccine enhances resistance against visceralizing L. major and L. donovani infection in susceptible BALB/c mice.
    Schroeder J; Brown N; Kaye P; Aebischer T
    PLoS Negl Trop Dis; 2011 Dec; 5(12):e1406. PubMed ID: 22216363
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunotherapy for visceral leishmaniasis: A trapeze of balancing counteractive forces.
    Mazire PH; Saha B; Roy A
    Int Immunopharmacol; 2022 Sep; 110():108969. PubMed ID: 35738089
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genome based screening of epitope ensemble vaccine candidates against dreadful visceral leishmaniasis using immunoinformatics approach.
    Singh G; Pritam M; Banerjee M; Singh AK; Singh SP
    Microb Pathog; 2019 Nov; 136():103704. PubMed ID: 31479726
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis.
    Samant M; Gupta R; Kumari S; Misra P; Khare P; Kushawaha PK; Sahasrabuddhe AA; Dube A
    J Immunol; 2009 Jul; 183(1):470-9. PubMed ID: 19542458
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Induction of protective cellular immune responses against experimental visceral leishmaniasis mediated by dendritic cells pulsed with the N-terminal domain of Leishmania infantum elongation factor-2 and CpG oligodeoxynucleotides.
    Agallou M; Pantazi E; Tsiftsaki E; Toubanaki DK; Gaitanaki C; Smirlis D; Karagouni E
    Mol Immunol; 2018 Nov; 103():7-20. PubMed ID: 30173073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.